Natalie Barretto1, Hanwen Zhang2, Samuel K Powell1, Michael B Fernando1, Siwei Zhang2, Erin K Flaherty1, Seok-Man Ho1, Paul A Slesinger3, Jubao Duan4, Kristen J Brennand5. 1. Graduate School of Biomedical Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. Center for Psychiatric Genetics, NorthShore University HealthSystem, Evanston, IL, USA; Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA. 3. Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Center for Psychiatric Genetics, NorthShore University HealthSystem, Evanston, IL, USA; Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA. Electronic address: jduan@uchicago.edu. 5. Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: kristen.brennand@mssm.edu.
Abstract
BACKGROUND: Somatic cell reprogramming is routinely used to generate donor-specific human induced pluripotent stem cells (hiPSCs) to facilitate studies of disease in a human context. The directed differentiation of hiPSCs can generate large quantities of patient-derived cells; however, such methodologies frequently yield heterogeneous populations of neurons and glia that require extended timelines to achieve electrophysiological maturity. More recently, transcription factor-based induction protocols have been show to rapidly generate defined neuronal populations from hiPSCs. NEW METHOD: In a manner similar to our previous adaption of NGN2-glutamatergic neuronal induction from hiPSC-derived neural progenitor cells (NPCs), we now adapt an established protocol of lentiviral overexpression of ASCL1 and DLX2 to hiPSC-NPCs. RESULTS: We demonstrate induction of a robust and highly pure population of functional GABAergic neurons (iGANs). Importantly, we successfully applied this technique to hiPSC-NPCs derived from ten donors across two independent laboratories, finding it to be an efficient and highly reproducible approach to generate induced GABAergic neurons. Our results show that, like hiPSC-iGANs, NPC-iGANs exhibit increased GABAergic marker expression, electrophysiological maturity, and have distinct transcriptional profiles that distinguish them from other cell-types of the brain. Nonetheless, until donor-matched hiPSCs-iGANs and NPC-iGANs are directly compared, we cannot rule out the possibility that subtle differences in patterning or maturity may exist between these populations; one should always control for cell source in all iGAN experiments. CONCLUSIONS: This methodology, relying upon an easily cultured starting population of hiPSC-NPCs, makes possible the generation of large-scale defined co-cultures of induced glutamatergic and GABAergic neurons for hiPSC-based disease models and precision drug screening.
BACKGROUND: Somatic cell reprogramming is routinely used to generate donor-specific human induced pluripotent stem cells (hiPSCs) to facilitate studies of disease in a human context. The directed differentiation of hiPSCs can generate large quantities of patient-derived cells; however, such methodologies frequently yield heterogeneous populations of neurons and glia that require extended timelines to achieve electrophysiological maturity. More recently, transcription factor-based induction protocols have been show to rapidly generate defined neuronal populations from hiPSCs. NEW METHOD: In a manner similar to our previous adaption of NGN2-glutamatergic neuronal induction from hiPSC-derived neural progenitor cells (NPCs), we now adapt an established protocol of lentiviral overexpression of ASCL1 and DLX2 to hiPSC-NPCs. RESULTS: We demonstrate induction of a robust and highly pure population of functional GABAergic neurons (iGANs). Importantly, we successfully applied this technique to hiPSC-NPCs derived from ten donors across two independent laboratories, finding it to be an efficient and highly reproducible approach to generate induced GABAergic neurons. Our results show that, like hiPSC-iGANs, NPC-iGANs exhibit increased GABAergic marker expression, electrophysiological maturity, and have distinct transcriptional profiles that distinguish them from other cell-types of the brain. Nonetheless, until donor-matched hiPSCs-iGANs and NPC-iGANs are directly compared, we cannot rule out the possibility that subtle differences in patterning or maturity may exist between these populations; one should always control for cell source in all iGAN experiments. CONCLUSIONS: This methodology, relying upon an easily cultured starting population of hiPSC-NPCs, makes possible the generation of large-scale defined co-cultures of induced glutamatergic and GABAergic neurons for hiPSC-based disease models and precision drug screening.
Authors: Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth Journal: Nucleic Acids Res Date: 2015-01-20 Impact factor: 16.971
Authors: Ramon Pla; Amelia Stanco; MacKenzie A Howard; Anna N Rubin; Daniel Vogt; Niall Mortimer; Inma Cobos; Gregory Brian Potter; Susan Lindtner; James D Price; Alex S Nord; Axel Visel; Christoph E Schreiner; Scott C Baraban; David H Rowitch; John L R Rubenstein Journal: Cereb Cortex Date: 2018-11-01 Impact factor: 5.357
Authors: Nathan G Skene; Julien Bryois; Trygve E Bakken; Gerome Breen; James J Crowley; Héléna A Gaspar; Paola Giusti-Rodriguez; Rebecca D Hodge; Jeremy A Miller; Ana B Muñoz-Manchado; Michael C O'Donovan; Michael J Owen; Antonio F Pardiñas; Jesper Ryge; James T R Walters; Sten Linnarsson; Ed S Lein; Patrick F Sullivan; Jens Hjerling-Leffler Journal: Nat Genet Date: 2018-05-21 Impact factor: 38.330
Authors: Samuel K Powell; Callan O'Shea; Kayla Townsley; Iya Prytkova; Kristina Dobrindt; Rahat Elahi; Marina Iskhakova; Tova Lambert; Aditi Valada; Will Liao; Seok-Man Ho; Paul A Slesinger; Laura M Huckins; Schahram Akbarian; Kristen J Brennand Journal: Mol Psychiatry Date: 2021-09-07 Impact factor: 13.437
Authors: George Andrew S Inglis; Ying Zhou; Dillon G Patterson; Christopher D Scharer; Yanfei Han; Jeremy M Boss; Zhexing Wen; Andrew Escayg Journal: Hum Mol Genet Date: 2020-08-29 Impact factor: 6.150
Authors: Verica Vasic; Mattson S O Jones; Denise Haslinger; Lisa S Knaus; Michael J Schmeisser; Gaia Novarino; Andreas G Chiocchetti Journal: Genes (Basel) Date: 2021-10-30 Impact factor: 4.141
Authors: Kristina Dobrindt; Daisy A Hoagland; Carina Seah; Bibi Kassim; Callan P O'Shea; Marina Iskhakova; Michael B Fernando; P J Michael Deans; Samuel K Powell; Ben Javidfar; Aleta Murphy; Cyril Peter; Rasmus Møeller; Meilin Fernandez Garcia; Masaki Kimura; Kentaro Iwasawa; John Crary; Darrell N Kotton; Takanori Takebe; Laura M Huckins; Benjamin R tenOever; Schahram Akbarian; Kristen J Brennand Journal: bioRxiv Date: 2020-09-21
Authors: Jakob Unterholzner; Vincent Millischer; Christoph Wotawa; Akira Sawa; Rupert Lanzenberger Journal: Int J Neuropsychopharmacol Date: 2021-10-23 Impact factor: 5.176